Physician profile
Ashraf Uzzaman
NPI 1568624773
$1,283.64
in general payments reported to CMS, 2019-2025
16 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.28 · 2020: $50.73 · 2021: $209 · 2022: $151 · 2023: $203 · 2024: $321 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $371.37 | 2019-2025 | Tezspire, Airsupra |
| Genzyme Corporation | $256.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $187.24 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $142.76 | 2021-2024 | Dupixent |
| Pfizer INC. | $46.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2021-2022 | |
| Kaleo, INC. | $38.45 | 2020-2021 | |
| Amgen INC. | $34.75 | 2021-2022 | |
| Covis Pharma Gmbh | $29.68 | 2021 | |
| Genentech USA, INC. | $28.53 | 2023-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $24.15 | 2025 | Neffy |
| Optinose US, INC. | $21.93 | 2024 | |
| Uswm, LLC | $20.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2021 | |
| Merck Sharp & Dohme LLC | $14.43 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $13.18 | 2023 | Cutaquig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Uzzaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.